As Novo Nordisk and Eli Lilly expand sales of their popular diabetes and weight-loss drugs, cheaper copies of their patented ...

As Novo Nordisk and Eli Lilly expand sales of their popular diabetes and weight-loss drugs, cheaper copies of their patented ...

As Novo Nordisk and Eli Lilly expand sales of their popular diabetes and weight-loss drugs, cheaper copies of their patented ...

Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 480.21% and ...

MSD is also betting on Hansoh’s candidate working in more indications than just obesity. The drugmaker already has a ...

When individual investors are asked about investment vehicles for “innovation,” the Invesco QQQ ETF and the ARKK Innovation ...

Merck gets exclusive global rights to develop, manufacture and commercialize GLP-1 receptor agonist, HS-10535, from Hansoh ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

The big pharma is paying Hansoh $112 million upfront to place its bet on oral GLP-1 receptor agonist HS-1035, with another $1 ...

The U.S. Food and Drug Administration reissued a decision first made by the agency in October that a shortage of the diabetes ...

From Amazon.com's workers strike to Micron's weak earnings, here's a look at some of the major developments from across the world.